Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
[PDF][PDF] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
KT Flaherty, JR Infante, A Daud, R Gonzalez… - N Engl J Med, 2012 - Citeseer
Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud… - New England …, 2012 - scholars.northwestern.edu
BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud… - … England Journal of …, 2012 - researchers.mq.edu.au
BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud… - The New England …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
KT Flaherty, JR Infante, A Daud… - New England Journal …, 2012 - escholarship.org
BackgroundResistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
[PDF][PDF] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
KT Flaherty, JR Infante, A Daud, R Gonzalez… - N Engl J …, 2012 - researchgate.net
Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
[引用][C] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
KT FLAHERTY, JR INFANTE… - The New England …, 2012 - pascal-francis.inist.fr
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
KT Flaherty, JR Infante, A Daud… - The New England …, 2012 - europepmc.org
Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …
[引用][C] Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, N Ibrahim, JR Infante, HA Burris… - New England Journal …, 2012 - elibrary.ru